

Cassie Pan, MD

1. PERSONAL DATA

Legal Name: Cassie Pan

Place of Birth: Worcester, Massachusetts

2. EDUCATION

08/2010-05/2014 BS, Chemistry, Yale University, New Haven, CT

08/2014-05/2019 MD, Yale School of Medicine, New Haven, CT

3. POSTGRADUATE TRAINING

06/2019-06/2025 Residency, Otolaryngology – Head & Neck Surgery, University of Washington, Seattle, WA

07/2021-06/2022 Postdoctoral Research Fellowship, Department of Otolaryngology – Head & Neck Surgery, University of Washington, Seattle, WA (T32 DC000018)

09/2021-06/2022 Certificate in Clinical Trials, University of Washington, Seattle, WA

07/2025-07/2026 Fellowship, Head and Neck Surgical Oncology and Microvascular Reconstruction, Vanderbilt University Medical Center, Nashville, TN

4. FACULTY POSITIONS HELD

10/2026- Assistant Professor, Otolaryngology – Head & Neck Surgery, University of Washington, Seattle, WA

5. HOSPITAL POSITIONS HELD

07/2025-07/2026 Clinical Instructor, Otolaryngology – Head & Neck Surgery, Vanderbilt University Medical Center, Nashville, TN

6. HONORS

12/2013 Phi Beta Kappa Honor Society, Yale University

08/2013-05/2014 Science, Technology, and Research Scholars Fellow, Yale University

05/2014 Howard Douglass Moore Prize, Chemistry Departmental Graduation Award, Yale University

05/2014 Graduated Summa Cum Laude, Yale University

10/2018 Honorable Mention in Head and Neck Surgery Poster Presentation, American Academy of Otolaryngology-Head and Neck Surgery

03/2019 Yale International Clinical Elective Travel Fellow, Yale School of Medicine

7. BOARD CERTIFICATION

None

8. CURRENT LICENSE(S) TO PRACTICE

09/2026-Present Washington State Medical License

9. CONTRIBUTIONS TO BELONGING, INCLUSION, AND COMMUNITY (Optional)

08/2015-08/2016 Executive Board Member, HAVEN Free Clinic, Yale School of Medicine, New Haven, CT. Student-run free clinic serving uninsured and underserved patients in New Haven.

10. PROFESSIONAL ORGANIZATIONS

2019-Present American Academy of Otolaryngology – Head & Neck Surgery
2022-Present Triological Society
2023-Present American Head and Neck Society
2023-Present American Rhinologic Society

11. EDUCATION AND TRAINING ACTIVITIES

a. Didactic Teaching

08/2012-05/2013 Physical Chemistry I & II Undergraduate Course Tutor, Yale University
08/2015 Student Leader, Introduction to the Profession Master Course, Yale School of Medicine

b. Thesis Committee Membership

None

c. Advising/Mentorship

07/2022-06/2025 Mentor, Women in Surgery, University of Washington, Seattle, WA

d. Curriculum and Training Program Development

09/2022-03/2023 Course Director, Northwest Airway Course, Seattle, WA

e. Other

06/2014-07/2014 English Teacher, Colegio Salesiano San Juan Bosco, Barcelona, Spain

12. EDITORIAL RESPONSIBILITIES

a. Editorial Boards

None

b. Ad Hoc Reviewing Responsibilities

None

13. SPECIAL RESPONSIBILITIES AND SERVICE

a. International

None

b. National

07/2021-06/2022 Member, Trauma Committee, American Academy of Otolaryngology – Head and Neck Surgery

c. Regional

None

d. University of Washington

07/2023-06/2025 Elected Resident Representative, Program Evaluation Committee, University of Washington, Otolaryngology – Head and Neck Surgery, Seattle, WA

14. CLINICAL ACTIVITIES

I am appointed as an Assistant Professor with 0.25 FTE at UW and 0.75 FTE at the VA Puget Sound. At both sites, I spend one day/week in head and neck surgery clinic and one day/week in the OR. One additional day per week is spent on clinical and administrative duties at the VA. I staff Otolaryngology consults as needed every day depending on which site I am located at.

15. RESEARCH FUNDING

a. Active

None

b. Pending

None

c. Past

1. Source: National Institutes of Health (NIH)/National Institute on Deafness and Other Communication Disorders (NIDCD) T32 Research Training Grant (DC000018)

PI: Jennifer Stone, PhD

Funding Period: 07/01/2021-06/30/2022

Amount: \$60,000

2. Sponsor: Blaze Bioscience

Title: Intraoperative visualization of oral cavity squamous cell carcinoma and high-grade dysplasia with tozeristide, a fluorescent tumor marking agent

Funding Period: 07/2022-07/2026

Amount: \$200,000

Role: Sub-Investigator

16. BIBLIOGRAPHY

a. Peer-Reviewed Manuscripts

1. Hwang S-A, **Pan C**, Boyd S, Pellis NR, Actor JK. Modeled microgravity conditions suppress innate macrophage and lymphocytic responses to common mitogens and Mycobacterium tuberculosis infection. *Gravit Space Res.* 2012;26(1):25-33.
2. Koehne I, Schmeier TJ, Bielinski EA, **Pan CJ**, Lagaditis PO, Bernskoetter WH, Takase MK, Wurtele C, Hazari N, Schneider S. Synthesis and structure of six-coordinate iron borohydride complexes supported by PNP ligands. *Inorg Chem.* 2014;53(4):2133-2143. PMID: 24499462.
3. Fillman KL, Bielinski EA, Schmeier TJ, Nesvet JC, Woodruff TM, **Pan CJ**, Takase MK, Hazari N, Neidig ML. Flexible binding of PNP pincer ligands to monomeric iron complexes. *Inorg Chem.* 2014;53(12):6066-6072. PMID: 24878059.
4. Imoisili OE, Levinsohn E, **Pan C**, Howell BA, Streiter S, Rosenbaum JR. Discrepancy between patient health literacy levels and readability of patient education materials from an electronic health record. *Health Lit Res Pract.* 2017;1(4):203-207. PMID: 31294265.

5. **Pan C**, Yarbrough WG, Issaeva N. Advances in biomarkers and treatment strategies for HPV-associated head and neck cancer. *Oncoscience*. 2018;5(5-6):140-141. PMID: 30035167.
6. **Pan C**, Sewell A, Michaelides E. Endoscope-assisted resection of intravestibular schwannoma: a video case report. *Laryngoscope*. 2018;129(4):986-988. PMID: 30575039.
7. **Pan C**, Issaeva N, Yarbrough WG. HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis. *Cancers Head Neck*. 2018;3:12. PMID: 31093365.
8. **Pan C**, Izreig S, Yarbrough WG, Issaeva N. NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents. *Cancers Head Neck*. 2019;4:3. PMID: 31321084.
9. **Pan C**, Wu QV, Voutsinas J, Houlton JJ, Barber B, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm JR, Rodriguez CP. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat. *Head Neck*. 2022;45(2):391-397. PMID: 36412064.
10. **Pan C**, Wu QV, Voutsinas J, Houlton JJ, Barber B, Rizvi ZH, Marchiano E, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm JR, Rodriguez CP. Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors. *Cancer Medicine*. 2023;12(8):9384-9391. PMID: 36806947.
11. **Pan C**, Andrews LIB, Johnson E, Bhatt NK, Rizvi ZH. Factors associated with successful electrolarynx use after total laryngectomy, a multi-institutional study. *Laryngoscope Investig Otolaryngol*. 2024;9(1):e1212. PMID: 38362175.
12. **Pan C**, Ng K, Voutsinas J, Barber B, Rizvi ZH, Marchiano E, Ferrandino RM, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Martins RG, Rodriguez CP, Wu QV. Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. *BMC Cancer*. 2024;24(1):1406. PMID: 39543541.
13. Zhou P, Yeshoua BJ, Konuthula N, **Pan CJ**, Ferrandino RM, Holte SE, Rizvi Z, Marchiano EJ, Futran ND, Barber BR. Association of oral health determinants with oral squamous cell carcinoma in never-smoking adults. *Head Neck*. 2025;47(7):2025-2032. PMID: 40022306.
14. Clements AC, **Pan C**, Bhatt N, Roth M, Barber B, Marchiano E. Thyroid cartilage reconstruction with titanium mesh in advanced papillary thyroid carcinoma. *Laryngoscope*. 2026 Jun 23. Epub ahead of print. PMID: 42337848.
15. Austerlitz J, Radevic A, McAdoo A, Golliday K, **Pan C**, Moroco A, Roark S, Topf M. Complete pathologic response to neoadjuvant pembrolizumab captured on intraoperative PET/CT: a case report and exploratory analysis. *Head Neck*. 2026 Sep 3. Epub ahead of print. PMID: 42693001.

b. MedEdPortal Publications

None

c. Book Chapters

1. **Pan C**, Rizvi Z. Oral Cancer: What the General Surgeon Should Know. *Surg Clin North Am*. 2022;102(2):309-324. PMID: 35344699.

d. Published Books, Videos, Software, etc.

None

e. Other Publications

None

f. Manuscripts Under Review

1. Submission date: 05/2026. Radevic A, Austerlitz J, Sridhar S, Jin W, Ely KA, Mehrad M, Alabkaa A, Roark S, Moroco A, **Pan C**, Langerman AJ, Rohde SL, Sinard R, Mannion K, Topf M. Specimen orientation and margin sampling disagreement in head and neck cancer surgery.
2. Submission date: 06/2026. Alkhatib HH, Azadbakht J, Tang K, **Pan C**, Ferrandino R, Marchiano EJ, Rizvi ZH, Shih LC, Futran N, Old MO, Iravani A, Barber B, Rodriguez CP. Pretreatment PET/CT SUVmax and immunotherapy response in recurrent or metastatic head and neck cancer.
3. Submission date: 07/2026. Burns CR, Mannion K, Rohde SL, Sinard RJ, Topf MC, Yang SF, Rosenthal EL, **Pan C**. Where you live matters: a spatial analysis of head and neck cancer clinical trial disparities.
4. Submission date: 07/2026. **Pan C**, Zhou P, Barber BR, Ferrandino RM, Futran N, Rizvi ZR, Harrington K, Schmidt K, Wu QV, Bandhlish A, Rodriguez CP, Marchiano EJ. Intraoperative visualization of oral cavity squamous cell carcinoma and high-grade dysplasia with tozuleristide, a fluorescent tumor marking agent: a Phase I/II clinical trial.
5. Submission date: 10/2026. Kong J, Bischoff L, Ely K, Mannion K, **Pan C**. Macrofollicular variant of follicular thyroid carcinoma: an aggressive course of multifocal recurrence.

g. Abstracts

See Talks and Presentations (Section 17b) for conference abstracts and presentations.

17. TALKS AND PRESENTATIONS

a. Invited Talks and Presentations

None

b. Other Conference Presentations

Oral (Podium) Presentations

1. Sathe T, Hajek M, Sewell A, **Pan C**, Yarbrough W, Issaeva N. The role of TRAF3/CYLD mutations in the etiology of human papillomavirus-driven cancers of the head and neck. American Head and Neck Society Annual Meeting, Baltimore, MD, April 2018.
2. **Pan C**, Wu Q, Voutsinas J, Houlton JJ, Barber B, Futran N, Martins RG, Fromm J, Rodriguez CP. Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with outcomes among patients with recurrent metastatic head and neck squamous cell carcinoma and salivary gland cancer treated on a phase II trial of pembrolizumab and vorinostat. American Head & Neck Society Annual Meeting at COSM, Dallas, TX, April 2022.
3. **Pan C**, Wu Q, Houlton JJ, Barber B, Futran N, Rodriguez CP, Marchiano E. A phase I/II trial examining intraoperative visualization of oral cavity squamous cell carcinoma and high-grade dysplasia with tozuleristide, a fluorescent tumor marking agent. American Head & Neck Society Annual Meeting, Montreal, QC, July 2023.
4. **Pan C**, Wu Q, Voutsinas J, Ng K, Houlton JJ, Barber B, Rizvi ZH, Marchiano E, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Martins RG, Rodriguez CP. Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. American Head & Neck Society Annual Meeting, Montreal, QC, July 2023.
5. **Pan C**, Ng K, Voutsinas J, Norouzi A, Houlton JJ, Barber B, Rizvi ZH, Marchiano E, Ferrandino RM, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Rodriguez CP, Wu Q. Validation of a peripheral blood prognostic signature in HNSCC treated with immunotherapy and comparison to the systemic inflammatory response index. Triological Society Combined Sections Meeting, Orlando, FL, January 2025.

Poster Presentations

1. Imoisili OE, Howell BA, Streiter S, Levinsohn E, **Pan C**, Rosenbaum JR. A comparison of readability of electronic health record patient education materials and patient health literacy levels in a primary care clinic. American Academy on Communication in Healthcare Annual Conference, New Haven, CT, June 2016.
2. **Pan C**, Biktasova A, Hajek M, Sewell A, Sathe T, Bellinger G, Yarbrough W, Issaeva N. PARP-1 supports HPV infection and HPV-associated head and neck cancer. American Association for Cancer Research Annual Meeting, Chicago, IL, April 2018.
3. **Pan C**, Hajek M, Sewell A, Sathe T, Yarbrough WG, Issaeva N. Novel biomarkers as predictors of improved prognosis in human papillomavirus-associated head and neck cancer. American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, Atlanta, GA, October 2018.
4. **Pan C**, Wu Q, Voutsinas J, Houlton JJ, Barber B, Rizvi ZH, Marchiano E, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Fromm J, Rodriguez CP. Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancer treated with immune checkpoint inhibitors. Society for Immunotherapy of Cancer, Boston, MA, November 2022.
5. **Pan C**, Andrew LIB, Johnson E, Rizvi ZH. Factors associated with successful use of electrolarynx following total laryngectomy, a multi-institutional study. Triological Society Combined Sections Meeting, Coronado, CA, January 2023.
6. **Pan C**, Wu Q, Voutsinas J, Ng K, Norouzi A, Houlton JJ, Barber B, Rizvi ZH, Marchiano E, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Martins RG, Rodriguez CP. Development and validation of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. American Head & Neck Society Annual Meeting at COSM, Chicago, IL, May 2024.
7. Clements AC, **Pan C**, Bhatt N, Roth M, Barber B, Marchiano M. Preservation of Laryngeal Mucosa and Reconstruction of Thyroid Cartilage with Titanium Mesh in Advanced Papillary Thyroid Carcinoma. Triological Society Combined Sections Meeting, Orlando, FL, January 2026.

18. OTHER EMPLOYMENT

None